Q: Some pharmas are out of favor -- what's your take on Amylin (AMLN )?
A: The chart on AMLN looks moderately constructive. It's in a basing process. If it can jump back above the $26 level, the technicals would turn much more bullish. Relative to other pharmaceutical stocks, this one looks pretty good.
Q: How will Martha Stew